CLAIMS

1. A respiratory syncytial virus (RSV) fusion (F) protein encoded by a nucleic acid having the sequence of SEQ ID NO:7.

2. An RSV F protein comprising or consisting of the amino acid sequence of SEQ ID NO: 8, wherein said sequence is cleaved into F_1 and F_2 subunits which are disulphide linked.

3. An isolated nucleic acid encoding the RSV F protein according to claim 1 or claim 2.

4. A vector comprising the nucleic acid of claim 3.

5. An isolated cell comprising the nucleic acid of claim 3.

6. A micelle or Virus-Like-Particle (VLP) comprising an RSV F protein according to claim 1 or 2.

7. The micelle of claim 6, wherein the RSV F is cleaved into F_1 and F_2 subunits which are disulphide linked and wherein trimers of the F_1 and F_2 subunits form lollipop-shaped spikes of 19.6nm and micellar particles of 40.2 nm.

8. An immunogenic composition comprising the RSV F protein of claim 1 or 2 or the micelle or VLP of claim 6 or 7.

9. A pharmaceutically acceptable vaccine composition comprising the RSV F protein of claim 1 or 2 or the micelle or VLP of claim 6 or 7, wherein the RSV F protein is capable of eliciting an immune response in a host.

10. The immunogenic composition of claim 8 or vaccine composition of claim 9 wherein the composition comprises an adjuvant.

11. The immunogenic composition or vaccine composition of claim 10, wherein the adjuvant is alum.

12. An RSV F protein of claim 1 or 2 or a micelle or VLP of claim 6 or 7 in a pharmaceutically acceptable formulation for use in a method of vaccinating a mammal against an RSV infection.

13. The RSV F protein, micelle or VLP of claim 12 for use according to claim 12, wherein said formulation comprises an adjuvant.

14. The RSV F protein, micelle or VLP of claim 13 for use according to claim 13, wherein the adjuvant is alum.